| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18947 R80579 |
Razaz_Norway, 2026 | Neurodevelopmental disorders - One diagnosis for Intellectual disability (ICD-10: F70– F79), psychological development disorders (F80–F83), autism spectrum disorder (F84, excluding F84.2–F84.4), and ADHD (F90.0, F98.8) - Median age at the end of follow-up: 5.2 years | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | exposed to other treatment, sick | Adjustment: Yes Paternal ASMs: monotherapy | 1.20 [0.70;2.04] | 21/460 39/1,101 | 60 | 460 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18948 R80584 |
Razaz_Sweden, 2026 | Neurodevelopmental disorders - One diagnosis for Intellectual disability (ICD-10: F70– F79), psychological development disorders (F80–F83), autism spectrum disorder (F84, excluding F84.2–F84.4), and ADHD (F90.0, F98.8) - Median age at the end of follow-up: 6.6 years | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | exposed to other treatment, sick | Adjustment: Yes Paternal ASMs: monotherapy | 1.03 [0.82;1.30] | 159/1,500 247/2,906 | 406 | 1,500 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18654 R79276 |
Botton, 2025 | Neurodevelopmental disorders - ICD10: F90.x and/or methylphenidate prescription; ICD10: F84 (excl F84.2-F84.3); - Median follow up (years): 11.9 (IQR [10.3 - 13.3]) for valproate; 11.2 (IQR [9.9 - 12.8]) for control | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | retrospective cohort (claims database) | exposed to other treatment, sick | Adjustment: Yes Paternal ASMs: monotherapy | 1.17 [0.98;1.40] | 414/3,484 199/2,041 | 613 | 3,484 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18646 R79288 |
Christensen (Controls exposed to LTG/LEV), 2024 | Neurodevelopmental disorders - Intellectual disability, Disorders of psychological development, Autism spectrum disorders, ADHD - Median age [IQR] age at the end of follow-up: 10.6 [5.4-15.0] years for valproate; 5.5 [2.7-9.3] years for controls | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes Paternal ASMs: monotherapy |
1.02 [0.67;1.54] excluded (control group) |
67/961 50/1,401 | 117 | 961 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18644 R79233 |
Christensen (Controls unexposed, general pop), 2024 | Neurodevelopmental disorders - Intellectual disability, Disorders of psychological development, Autism spectrum disorders, ADHD - Median follow-up about 10 years (IQR 5-15) | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes Paternal ASMs: monotherapy |
1.13 [0.88;1.44] excluded (control group) |
-/1,017 51,437/1,234,017 | - | 1,017 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18647 R79253 |
Christensen (Controls unexposed, sibling), 2024 | Neurodevelopmental disorders - Intellectual disability, Disorders of psychological development, Autism spectrum disorders, ADHD - Median follow-up about 10 years (IQR 5-15) | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | sibling excluded | Adjustment: Yes Paternal ASMs: mono/polytherapy or not specified |
1.30 [0.51;3.31] excluded (control group) |
16/303 23/381 | 39 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18645 R79242 |
Christensen (Controls unexposed, sick), 2024 | Neurodevelopmental disorders - Intellectual disability, Disorders of psychological development, Autism spectrum disorders, ADHD - Median follow-up about 10 years (IQR 5-15) | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Paternal ASMs: mono/polytherapy or not specified | 1.09 [0.85;1.39] | 70/1,052 622/11,308 | 692 | 1,052 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.11 [0.99;1.25] | 1,771 | 6,496 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 18646, 18644, 18647